PRIMAQUINE TABLET

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

PRIMAQUINE PHOSPHATE

可用日期:

SANOFI-AVENTIS CANADA INC

ATC代码:

P01BA03

INN（国际名称）:

PRIMAQUINE

剂量:

26.3MG

药物剂型:

TABLET

组成:

PRIMAQUINE PHOSPHATE 26.3MG

给药途径:

ORAL

每包单位数:

100

处方类型:

Prescription

治疗领域:

ANTIMALARIALS

產品總結:

Active ingredient group (AIG) number: 0152571001; AHFS:

授权状态:

APPROVED

授权日期:

2001-04-02

产品特点

_Product Monograph – PRIMAQUINE _
_ _
_Page 1 of 24_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
PRIMAQUINE
®
Primaquine phosphate tablets, USP
26.3 mg primaquine phosphate (equivalent to 15 mg primaquine base)
Antimalarial
sanofi-aventis Canada Inc.
2905, Place Louis-R.-Renaud
Laval, Quebec H7V 0A3
Date of Revision:
May 27, 2020
Submission Control No: 226711
_Product Monograph – PRIMAQUINE _
_ _
_Page 2 of 24_
RECENT MAJOR LABEL CHANGES
Indications (1) 05/2020
Contraindications (2) 05/2020
Dosage and Administration, Recommended Dose and Dosage Adjustment
(3.2) 05/2020
Dosage and Administration, Missed Dose (3.4) 05/2020
Warnings and Precautions (6) 05/2020
Warnings and Precautions, Special Populations (6.1) 05/2020
TABLE OF CONTENTS
RECENT MAJOR LABEL CHANGES
......................................................................................2
TABLE OF CONTENTS
..............................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................4
1
INDICATIONS
..................................................................................................................4
1.1
Pediatrics
....................................................................................................................4
1.2
Geriatrics
....................................................................................................................4
2
CONTRAINDICATIONS
.................................................................................................4
3
DOSAGE AND ADMINISTRATION
.............................................................................5
3.1
Dosing Considerations
...............................................................................................5
3.2
Recommended Dose and Dosage Adjustment
...........................................................5
3.3
Administration
....................................................................